Development of Recombinant Sendai Virus Vaccines for Prevention of Human Parainfluenza and Respiratory Syncytial Virus Infections
- 1 October 2008
- journal article
- other
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 27 (10), S126-S128
- https://doi.org/10.1097/inf.0b013e318168b780
Abstract
Respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are the most important causes of hospitalization for viral respiratory tract diseases in infants and young children. Unfortunately, there are currently no licensed vaccines for prevention of these infections. Researchers at St. Jude Children's Research Hospital are now developing Sendai virus (SV), a natural respiratory pathogen of mice, as a Jennerian vaccine for hPIV-1, and as a vaccine backbone for the prevention of RSV and other hPIVs. Unmodified SV is currently being tested in the clinic. Thus far, the vaccine has been well tolerated. Preclinical studies also continue and have demonstrated that intranasal vaccinations with recombinant SV expressing an RSV antigen are sufficient to activate high-magnitude RSV-specific neutralizing B- and T-cell activities in a cotton rat system. Furthermore, vaccinated animals are completely protected against RSV challenges. As clinical safety studies progress, St. Jude Children's Research Hospital researchers are also working to formulate a SV-based cocktail vaccine designed to prevent several hPIV and RSV infections in humans.Keywords
This publication has 26 references indexed in Scilit:
- Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent WheezingThe Journal of Pediatrics, 2007
- Atypical Measles and Enhanced Respiratory Syncytial Virus Disease (ERD) Made SimplePediatric Research, 2007
- A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccinesNature Medicine, 2006
- Recombinant Sendai Virus as a Novel Vaccine Candidate for Respiratory Syncytial VirusViral Immunology, 2005
- Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSVJournal of Virology, 2004
- The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-BVaccine, 2003
- Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccineJournal of General Virology, 2001
- Immunopathology in RSV Infection Is Mediated by a Discrete Oligoclonal Subset of Antigen-Specific CD4+ T CellsImmunity, 2001
- Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type oneVaccine, 1997
- Human Parainfluenza Virus Type 1 Immunization of Infant Mice Protects from Subsequent Sendai Virus InfectionVirology, 1995